October 27, 2022

Patients with the A97S genotype of ATTR-CM may exhibit functional and structural improvements after tafamidis treatment. A recent case study showcased these potential benefits. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an under-recognized cause of heart failure. Mutations in the TTR gene are thought to destabilize and change the shape of the protein. Although under-represented in major...

In patients stabilized on tafamidis, SGLT2 inhibitors may be beneficial for improving outcomes of transthyretin amyloid cardiomyopathy (ATTR-CM). Treatment with dapagliflozin was found to be well-tolerated in patients with ATTR-CM. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart disease that can be fatal. In recent years, more and more people have been diagnosed and subsequently hospitalized...

Patients with sickle cell anemia (SCA) may be protected from severe disease with malaria. However, severe complications, such as severe drops in hemoglobin, may occur in SCA patients with concomitant low-density malarial infection. Sickle cell anemia (SCA) has historically been linked to high levels of childhood mortality in Africa, with malaria playing a significant role....

L-glutamine is an FDA-approved treatment for sickle cell disease. One study explored the potential benefits and mechanism of action of L-glutamine in sickle cell disease patients. Leukocytosis is common in sickle cell disease (SCD) in the absence of infection and is a predictor for increased risk of stroke, acute chest syndrome, and mortality. Oral L-glutamine...